Your browser doesn't support javascript.
loading
An economic evaluation of eribulin for advanced breast cancer treatment based on the Southeast Netherlands advanced breast cancer registry.
Pouwels, Xavier G L V; Ramaekers, Bram L T; Geurts, Sandra M E; Erdkamp, Frans; Vriens, Birgit E P J; Aaldering, Kirsten N A; van de Wouw, Agnes J; Dercksen, M W; Smilde, Tineke J; Peters, Natascha A J B; van Riel, J M G H; Pepels, Manon J; Heijnen-Mommers, Jose; Tjan-Heijnen, Vivianne C G; de Boer, Maaike; Joore, Manuela A.
Afiliación
  • Pouwels XGLV; Department of Clinical Epidemiology and Medical Technology Assessment (KEMTA), Maastricht University Medical Centre +, Maastricht, The Netherlands.
  • Ramaekers BLT; Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, The Netherlands.
  • Geurts SME; School of Oncology and Developmental Biology (GROW), Maastricht University, Maastricht, The Netherlands.
  • Erdkamp F; Department of Clinical Epidemiology and Medical Technology Assessment (KEMTA), Maastricht University Medical Centre +, Maastricht, The Netherlands.
  • Vriens BEPJ; School of Oncology and Developmental Biology (GROW), Maastricht University, Maastricht, The Netherlands.
  • Aaldering KNA; Division of Medical Oncology, Department of Internal Medicine, Maastricht University Medical Centre +, Maastricht, The Netherlands.
  • van de Wouw AJ; Department of Internal Medicine, Zuyderland Medical Centre, Sittard-Geleen, The Netherlands.
  • Dercksen MW; Department of Internal Medicine, Catharina Hospital, Eindhoven, The Netherlands.
  • Smilde TJ; Department of Internal Medicine, Laurentius Hospital, Roermond, The Netherlands.
  • Peters NAJB; Department of Internal Medicine, VieCuri Medical Center, Venlo, The Netherlands.
  • van Riel JMGH; Department of Internal Medicine, Máxima Medical Centre, Eindhoven, The Netherlands.
  • Pepels MJ; Department of Internal Medicine, Jeroen Bosch Hospital, Hertogenbosch, The Netherlands.
  • Heijnen-Mommers J; Department of Internal Medicine, Sint Jans Gasthuis, Weert, The Netherlands.
  • Tjan-Heijnen VCG; Department of Internal Medicine, Elisabeth-TweeSteden Hospital, Tilburg, The Netherlands.
  • de Boer M; Department of Internal Medicine, Elkerliek Hospital, Helmond, The Netherlands.
  • Joore MA; School of Oncology and Developmental Biology (GROW), Maastricht University, Maastricht, The Netherlands.
Acta Oncol ; 59(9): 1123-1130, 2020 Sep.
Article en En | MEDLINE | ID: mdl-32544366
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Protocolos de Quimioterapia Combinada Antineoplásica / Costos de los Medicamentos / Modelos Económicos / Furanos / Cetonas Tipo de estudio: Diagnostic_studies / Health_economic_evaluation / Prognostic_studies Límite: Female / Humans / Middle aged País/Región como asunto: Europa Idioma: En Revista: Acta Oncol Asunto de la revista: NEOPLASIAS Año: 2020 Tipo del documento: Article País de afiliación: Países Bajos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Protocolos de Quimioterapia Combinada Antineoplásica / Costos de los Medicamentos / Modelos Económicos / Furanos / Cetonas Tipo de estudio: Diagnostic_studies / Health_economic_evaluation / Prognostic_studies Límite: Female / Humans / Middle aged País/Región como asunto: Europa Idioma: En Revista: Acta Oncol Asunto de la revista: NEOPLASIAS Año: 2020 Tipo del documento: Article País de afiliación: Países Bajos